Quantbot Technologies LP acquired a new stake in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) in the second quarter, HoldingsChannel.com reports. The fund acquired 17,151 shares of the company’s stock, valued at approximately $438,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Azenta by 2,067.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after buying an additional 765 shares in the last quarter. State of Wyoming purchased a new position in Azenta during the first quarter valued at $38,000. Osaic Holdings Inc. increased its holdings in Azenta by 44.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock valued at $39,000 after acquiring an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in Azenta by 98.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after acquiring an additional 689 shares during the last quarter. Finally, Allworth Financial LP purchased a new stake in Azenta in the 2nd quarter worth $48,000. Institutional investors own 99.08% of the company’s stock.
Azenta Trading Down 2.0%
Shares of NASDAQ AZTA opened at $32.95 on Friday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The firm’s 50-day moving average price is $28.93 and its 200-day moving average price is $25.20. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -11.94 and a beta of 1.37.
Wall Street Analyst Weigh In
Several research analysts have commented on AZTA shares. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Needham & Company LLC increased their price target on Azenta from $33.00 to $37.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $41.20.
Read Our Latest Stock Analysis on AZTA
Azenta Profile
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Featured Articles
- Five stocks we like better than Azenta
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
